丹麦2005-2014年重大骨质疏松性骨折后治疗缺口:结合处方与医院给药抗骨质疏松药物的联合分析
该研究基于丹麦注册数据,纳入2005-2014年间≥50岁发生重大骨质疏松性骨折(MOF)的男女性,评估骨折后1年内未接受抗骨质疏松药物治疗的比例。结果显示治疗缺口从2005年85%降至2014年79%,纳入医院给药后未见显著改善,提示需加强骨折后二级预防组织。
要点
- MOF患者治疗缺口从2005年85%降至2014年79%,降幅有限。
- 髋部和椎体骨折患者缺口小于肱骨和前臂骨折,女性小于男性。
- 医院给药抗骨质疏松药物使用率低,最高仅0.9%(2012年)。
核心结论
- 重大骨质疏松性骨折患者中存在持续显著的治疗缺口,纳入医院给药抗骨质疏松药物未显著改善缺口评估。
- 亟需加强骨折后护理组织和二级骨折预防。
研究设计与样本
- 回顾性注册研究,纳入2005-2014年丹麦≥50岁发生至少一次MOF的男女性。
- 采用重复横断面设计,每年生成首次MOF、髋部、椎体、肱骨或前臂骨折患者队列。
主要发现
- MOF患者治疗缺口从2005年85%降至2014年79%。
- 髋部和椎体骨折患者缺口小于肱骨和前臂骨折患者,女性小于男性。
- 医院给药抗骨质疏松药物使用相对少见,MOF患者中最大比例为0.9%(2012年)。
- 医院给药抗骨质疏松药物在椎体骨折患者中最常用。
关键数值与推荐
- 治疗缺口定义为骨折后1年内未接受抗骨质疏松药物治疗的患者比例。
- 医院给药抗骨质疏松药物通过SKS代码识别。
临床怎么用
- 临床应加强骨折后二级预防组织,尤其关注肱骨、前臂骨折及男性患者。
- 评估治疗缺口时需考虑医院给药途径,但本研究中其影响有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study demonstrates a substantial and persistent anti-osteoporosis treatment gap in men and women ≥50 years old who sustained major osteoporotic fracture(s) between 2005 and 2014 in Denmark. This was not substantially reduced by including hospital-administered anti-osteoporosis treatments. Strengthened post-fracture organization of care and secondary fracture prevention is highly needed. INTRODUCTION: The purpose of this study was to evaluate the Danish anti-osteoporosis treatment gap from 2005 to 2014 in patients sustaining a major osteoporotic fracture (MOF), and to assess the impact of including hospital-administered anti-osteoporosis medications (AOM) on the treatment gap among these patients. METHODS: In this retrospective, registry-based study, we included men and women aged 50 years or older and living in Denmark, who sustained at least one MOF between 2005 and 2014. We applied a repeated cross-sectional design to generate cohorts of patients sustaining a first MOF, hip, vertebral, humerus, or forearm fracture, respectively, within each calendar year. We evaluated the treatment gap as the proportion of patients within each cohort not receiving treatment with AOM within 1 year of the fracture. Hospital-administered AOM was identified by SKS code. RESULTS: The treatment gap among MOF patients decreased from 85% in 2005 to 79% in 2014. The gap was smaller among hip and vertebral fracture patients as compared to humerus and forearm fracture patients, and it was smaller in women than in men. The use of hospital-administered AOM was relatively uncommon, with a maximum of 0.9% of MOF patients initiating hospital-administered AOM (in 2012). We observed substantial variations in this proportion between fracture types and gender. Hospital-administered AOM was most commonly used among vertebral fracture patients. CONCLUSION: A significant treatment gap among patients sustaining a major osteoporotic fracture was present throughout our analysis, and including hospital-administered AOM did not significantly improve the treatment gap assessment. Improved secondary fracture prevention is urgently needed.
引用
- Skjødt MK, Ernst MT, Khalid S, et al. The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. Osteoporos Int. 2021. PMID: 33721032. doi:10.1007/s00198-021-05890-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。